The fact
This regulatory authorization expands the therapeutic indications of the treatment and strengthens the French laboratory's commercial position.
Dupixent represents an expansion of Sanofi's pharmaceutical portfolio in inflammatory diseases.
17 sources — click a link to read an article on the topic:
Story timeline
Apr 13Sanofi wins EU approval for Dupixent in chronic urticariathis article